Posted On: 02/25/2015 7:18:51 PM
Post# of 30067
Re: Mkerryfuller #17224
My concerns have to do with a few things Gerald has talked about for the past few years, but fails to deliver on.
- Non-dilutive funding
- Grants
- Unlocking shareholder value
- Financial engineering
- Saying a r/s may not be necessary to uplist (ha!)
It is neat that AMBS has acquired some nice products recently, but the bottom line is we have no way to pay for them, besides handing out shares.
The recent hires and appointments are also nice, but we also have no way to pay them.
We can't keep spending and be a successful company without bringing in some money. It is simple economics. For the past few years, there hasn't been a dime brought in without dilution.
I hope I am very wrong, but I don't see Lympro bringing in nearly enough revenue to sustain operations without further dilution. The reason I stick around is the same as many other shareholders: We think on any given day GC could drop a bomb about some very significant non-dilutive monies.
- Non-dilutive funding
- Grants
- Unlocking shareholder value
- Financial engineering
- Saying a r/s may not be necessary to uplist (ha!)
It is neat that AMBS has acquired some nice products recently, but the bottom line is we have no way to pay for them, besides handing out shares.
The recent hires and appointments are also nice, but we also have no way to pay them.
We can't keep spending and be a successful company without bringing in some money. It is simple economics. For the past few years, there hasn't been a dime brought in without dilution.
I hope I am very wrong, but I don't see Lympro bringing in nearly enough revenue to sustain operations without further dilution. The reason I stick around is the same as many other shareholders: We think on any given day GC could drop a bomb about some very significant non-dilutive monies.
(0)
(0)
